<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03471624</url>
  </required_header>
  <id_info>
    <org_study_id>45054</org_study_id>
    <nct_id>NCT03471624</nct_id>
  </id_info>
  <brief_title>Treatment Outcomes in Chronic Hepatitis B Patients on Sequential Therapy With Tenofovir Alafenamide (TAF)</brief_title>
  <official_title>Treatment Outcomes in Chronic Hepatitis B Patients on Sequential Therapy With Tenofovir Alafenamide (TAF)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Stanford University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Gilead Sciences</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Stanford University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Primary Objective:

      To describe rate of persistence and/or improvement of viral suppression with TAF as with
      previous anti-HBV (hepatitis B virus) treatment
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Secondary Objective(s):

        1. Describe persistence of ALT (alanine aminotransferase) normalization and/or improvement
           of ALT levels with TAF as with previous anti-HBV treatment

        2. To describe trends in serum creatinine and calculated creatinine clearance as available
           by local labs.

        3. To describe trends in bone mass from baseline to 24 months after switch.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">April 2018</start_date>
  <completion_date type="Anticipated">April 2021</completion_date>
  <primary_completion_date type="Anticipated">April 2020</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Improvement and/or Persistence of Viral Suppresion</measure>
    <time_frame>24 months</time_frame>
    <description>To describe rate of persistence and/or improvement of viral suppression with TAF as with previous anti-HBV treatment</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>ALT Normalization and/or Improvement</measure>
    <time_frame>24 months</time_frame>
    <description>To describe persistence of ALT normalization and/or improvement of ALT levels with TAF as with previous anti-HBV treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Creatinine Clearance Trends</measure>
    <time_frame>24 months</time_frame>
    <description>To describe trends in calculated creatinine clearance as available by local labs.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum Creatinine Trends</measure>
    <time_frame>24 months</time_frame>
    <description>To describe trends in serum creatinine as available by local labs.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Bone Mass Density Trends</measure>
    <time_frame>24 months</time_frame>
    <description>To describe trends in bone mass density from baseline to end of study.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">251</enrollment>
  <condition>Hepatitis B, Chronic</condition>
  <arm_group>
    <arm_group_label>Tenofovir Alafenamide for 24 months</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects on any antiviral treatment for chronic HBV who plan to be switched by their physician to be treated with TAF 25 mg for 24 months.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tenofovir Alafenamide</intervention_name>
    <description>Tenofovir alafenamide (TAF) is a new formulation of tenofovir with higher intracellular active drug concentration allowing for dosing of only 25 mg once daily and thus can potentially lower the already low risk of renal toxicity and bone loss with tenofovir disoproxil fumarate (TDF).</description>
    <arm_group_label>Tenofovir Alafenamide for 24 months</arm_group_label>
    <other_name>Vemlidy</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:

          1. Male or female, age ≥18 years

          2. CHB (chronic hepatitis B) diagnosis confirmed by positive HBsAg or HBV DNA or HBeAg or
             documented history of CHB in physician note

          3. Currently maintained on antiviral therapy for at least 48 weeks with any HBV DNA value
             at Screening/Baseline and planned to be switched to TAF by their physician

          4. Routinely monitored for serum HBV DNA PCR (polymerase chain reaction), liver chemistry
             including AST (aspartate aminotransferase )/ALT/total bilirubin, renal chemistry
             including BUN (blood urea nitrogen)/Cr/CO2 (carbon dioxide) by their physicians every
             3-6 months and a bone density scan at least every 2 years as per routine clinical care
             (one at baseline and one 2 years after switch).

          5. Estimated creatinine clearance &gt; 15 ml/min (using the Cockcroft-Gault method) at
             Screening/Baseline Visit. (Note: multiply estimated rate by 0.85 for women).

          6. Willing and able to provide informed consent

          7. Able to comply with dosing instructions for study drug administration and able to
             complete the study schedule of assessments

        Exclusion criteria:

          1. Pregnant women, women who are breastfeeding or who believe they may wish to become
             pregnant during the course of the study

          2. Previous recipient of a liver transplant

          3. Co-infection with human immunodeficiency virus (HIV) or hepatitis C (HCV) or hepatitis
             D (HDV)

          4. Severe or uncontrolled comorbidities

          5. Current or known hepatic decompensation (≤2 years) (e.g ascites, encephalopathy, or
             variceal hemorrhage) with a Child-Pugh score of B or C

          6. Malignancy including liver cancer within 5 years except cancers curable by surgical
             resection (e.g. basal cell skin cancer and squamous cell cancer)

          7. On any of the disallowed concomitant medications listed in the prior and concomitant
             medications list (pg. 11). Subjects on prohibited medications who are otherwise
             eligible will need a wash out period of at least 30 days prior to the
             Screening/Baseline visit.

          8. Males and females of reproductive potential who are unwilling to use &quot;effective&quot;
             protocol-specified method(s) of contraception during the study.

          9. Current substance or alcohol abuse judged by the investigator to potentially interfere
             with subject compliance.

         10. Any other clinical conditions that, in the opinion of the Investigator, would make the
             subject unsuitable or unable to comply with any of the study procedures
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mindie H Nguyen, MD,MAS</last_name>
    <role>Principal Investigator</role>
    <affiliation>Stanford University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Mindie H Nguyen, MD,MAS</last_name>
    <phone>650-736-1731</phone>
    <email>mindiehn@stanford.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Akiko Mizuta, B.A.</last_name>
    <phone>650-736-1731</phone>
    <email>amizuta@stanford.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Stanford University Medical Center</name>
      <address>
        <city>Palo Alto</city>
        <state>California</state>
        <zip>94304</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Mindie H Nguyen, MD,MAS</last_name>
      <phone>650-736-1731</phone>
      <email>mindiehn@stanford.edu</email>
    </contact>
    <contact_backup>
      <last_name>Akiko Mizuta, B.A.</last_name>
      <phone>6507361731</phone>
      <email>amizuta@stanford.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Mindie H Nguyen, MD,MAS</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>San Jose Gastroenterology</name>
      <address>
        <city>San Jose</city>
        <state>California</state>
        <zip>95128</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Huy N Trinh, MD</last_name>
      <phone>408-347-9001</phone>
      <email>htrinh@sjgi.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Kyushu University Hospital</name>
      <address>
        <city>Fukuoka</city>
        <zip>812-8582</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Norihiro Furusyo, MD, PhD.</last_name>
      <phone>81-92-642-5909</phone>
      <email>furusyo@gim.med.kyushu-u.ac.jp</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Nagoya City University</name>
      <address>
        <city>Nagoya</city>
        <zip>467-8601</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Yasuhito Tanaka, MD, PhD</last_name>
      <phone>81-52-853-8191</phone>
      <email>ytanaka@med.nagoya-cu.ac.jp</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Osaka City University</name>
      <address>
        <city>Osaka</city>
        <zip>545-8585</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Masaru Enomoto, MD, PhD</last_name>
      <phone>81-6-6645-3905</phone>
      <email>enomoto-m@med.osaka-cu.ac.jp</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Saga University Hospital</name>
      <address>
        <city>Saga</city>
        <zip>849-8501</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Yuichiro Eguchi, MD, PhD</last_name>
      <phone>81-952-34-3010</phone>
      <email>eguchiyu@cc.saga-u.ac.jp</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hanyang University Seoul Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>04736</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nowon Eulji Medical Center, Eulji University College of Medicine,</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Sang Bing Ahn, MD, PhD</last_name>
      <email>dr486@hanmail.net</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Sanggye Paik Hospital, Inje University College of Medicine</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Eileen L. Yoon, MD, PhD</last_name>
      <email>mseileen80@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Kaohsiung Medical University Hospital</name>
      <address>
        <city>Kaohsiung</city>
        <zip>807</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Ming-Lung Yu, MD, PhD</last_name>
      <phone>886-931931194</phone>
      <email>fish6069@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>E-Da Hospital</name>
      <address>
        <city>Kaohsiung</city>
        <zip>82445</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Cheng-Hao Tseng, MD, PhD</last_name>
      <phone>886-975-106-256</phone>
      <email>chenghaug@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>China Medical University Hospital</name>
      <address>
        <city>Taichung</city>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Cheng-Yuan Peng, MD, PhD</last_name>
      <phone>886-4-2205-2121</phone>
      <phone_ext>2264</phone_ext>
      <email>cypeng@mail.cmuh.org.tw</email>
    </contact>
  </location>
  <location_countries>
    <country>Japan</country>
    <country>Korea, Republic of</country>
    <country>Taiwan</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://www.gilead.com/~/media/files/pdfs/medicines/liver-disease/vemlidy/vemlidy_pi.pdf?la=en</url>
    <description>Vemlidy package insert</description>
  </link>
  <reference>
    <citation>Martin P, Lau DT, Nguyen MH, Janssen HL, Dieterich DT, Peters MG, Jacobson IM. A Treatment Algorithm for the Management of Chronic Hepatitis B Virus Infection in the United States: 2015 Update. Clin Gastroenterol Hepatol. 2015 Nov;13(12):2071-87.e16. doi: 10.1016/j.cgh.2015.07.007. Epub 2015 Jul 15. Review.</citation>
    <PMID>26188135</PMID>
  </reference>
  <reference>
    <citation>Lok AS, McMahon BJ, Brown RS Jr, Wong JB, Ahmed AT, Farah W, Almasri J, Alahdab F, Benkhadra K, Mouchli MA, Singh S, Mohamed EA, Abu Dabrh AM, Prokop LJ, Wang Z, Murad MH, Mohammed K. Antiviral therapy for chronic hepatitis B viral infection in adults: A systematic review and meta-analysis. Hepatology. 2016 Jan;63(1):284-306. doi: 10.1002/hep.28280. Epub 2015 Nov 13. Review.</citation>
    <PMID>26566246</PMID>
  </reference>
  <reference>
    <citation>Schweitzer A, Horn J, Mikolajczyk RT, Krause G, Ott JJ. Estimations of worldwide prevalence of chronic hepatitis B virus infection: a systematic review of data published between 1965 and 2013. Lancet. 2015 Oct 17;386(10003):1546-55. doi: 10.1016/S0140-6736(15)61412-X. Epub 2015 Jul 28. Review.</citation>
    <PMID>26231459</PMID>
  </reference>
  <reference>
    <citation>Weinbaum CM, Williams I, Mast EE, Wang SA, Finelli L, Wasley A, Neitzel SM, Ward JW; Centers for Disease Control and Prevention (CDC). Recommendations for identification and public health management of persons with chronic hepatitis B virus infection. MMWR Recomm Rep. 2008 Sep 19;57(RR-8):1-20.</citation>
    <PMID>18802412</PMID>
  </reference>
  <reference>
    <citation>Ward JW, Byrd KK. Hepatitis B in the United States: a major health disparity affecting many foreign-born populations. Hepatology. 2012 Aug;56(2):419-21. doi: 10.1002/hep.25799.</citation>
    <PMID>22532028</PMID>
  </reference>
  <reference>
    <citation>Sarin SK, Kumar M, Lau GK, Abbas Z, Chan HL, Chen CJ, Chen DS, Chen HL, Chen PJ, Chien RN, Dokmeci AK, Gane E, Hou JL, Jafri W, Jia J, Kim JH, Lai CL, Lee HC, Lim SG, Liu CJ, Locarnini S, Al Mahtab M, Mohamed R, Omata M, Park J, Piratvisuth T, Sharma BC, Sollano J, Wang FS, Wei L, Yuen MF, Zheng SS, Kao JH. Asian-Pacific clinical practice guidelines on the management of hepatitis B: a 2015 update. Hepatol Int. 2016 Jan;10(1):1-98. doi: 10.1007/s12072-015-9675-4. Epub 2015 Nov 13.</citation>
    <PMID>26563120</PMID>
  </reference>
  <reference>
    <citation>Terrault NA, Lok ASF, McMahon BJ, Chang KM, Hwang JP, Jonas MM, Brown RS Jr., Bzowej NH, Wong JB. Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance. Hepatology. 2018 Apr;67(4):1560-1599. doi: 10.1002/hep.29800.</citation>
    <PMID>29405329</PMID>
  </reference>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 7, 2018</study_first_submitted>
  <study_first_submitted_qc>March 13, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">March 20, 2018</study_first_posted>
  <last_update_submitted>March 30, 2018</last_update_submitted>
  <last_update_submitted_qc>March 30, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 3, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Stanford University</investigator_affiliation>
    <investigator_full_name>Mindie H. Nguyen</investigator_full_name>
    <investigator_title>Profesor of Medicine</investigator_title>
  </responsible_party>
  <keyword>Tenofovir alafenamide (TAF)</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis, Chronic</mesh_term>
    <mesh_term>Hepatitis B</mesh_term>
    <mesh_term>Hepatitis B, Chronic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tenofovir</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

